Stock Analysts

Q3 Results for Specialty Retail Continue

Ulta Beauty ULTA posted mixed Q3 earnings and forecast after the closing bell today, and stocks are down in late trading on the news. Earnings of $1.70 per share beat the Zacks consensus by 3 cents, while revenues of $1.34 billion were exactly in-line with expectations. Ecommerce was up 62% year over year, and guidance for Q2 has been raised from our $1.92 billion consensus, but shares are selling off in the after-hours based on lowered guidance for Q4 earnings. […]

Stock Analysts

U.S. Crude Export to Asia Swells: Is OPEC Losing the Game?

The increase in oil exports from the United States into the Asian markets can put pressure on the world markets as the supplies from OPEC may eventually be replaced with that of the United States. U.S. crude oil exports to Asia last week hit the highest in two months, and the second-highest on record, at 877,000 barrels per day (bpd), according to data from Kpler […]

Stock Analysts

Genpact (G) Touches 52-Week High on Expanding Clientele

Shares of Genpact Limited G touched 52-week high of $32.45, eventually closing at $32.01 on Nov 29, 2017. The stock has gained 31.5% year to date, substantially outperforming the 5.2% rally of the industry it belongs to. The outperformance can be attributed to expanding customer base as well as strong execution over the last four quarters. […]

Stock Analysts

Snapchat Gets New Look: Friends, Media Posts to Split

Snap Inc. SNAP announced that it is revamping its messaging application, Snapchat by separating posts made by friends and the ones made by publishers in an attempt to make the platform more user-friendly. Per the blog post, the right side of the app will have the Discover page covering Stories posted by brands and advertisers while the left side will feature a new page called “Friends” containing chats and Stories by friends […]

Stock Analysts

Medicines Company to Sell Infectious Disease Unit to Melinta

The Medicines Company MDCO announced that it has entered into a definitive agreement with antibiotics company, Melinta Therapeutics, Inc. MLNT , for selling its infectious disease business unit for an upfront payment of $270 million. The agreement will grant Melinta worldwide rights of Orbactiv, Minocin and recently launched Vabomere. […]